Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute.

PubWeight™: 1.03‹?› | Rank: Top 15%

🔗 View Article (PMID 17913443)

Published in Biomed Pharmacother on September 12, 2007

Authors

Christopher Lobo1, Gilberto Lopes, Orlando Silva, Stefan Gluck

Author Affiliations

1: Division of Hematology/Oncology, Braman Family Breast Cancer Institute, UMSylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, 1475 NW 12th Avenue, Suite 3510, Miami, FL 33136, USA.

Articles by these authors

Planning cancer control in Latin America and the Caribbean. Lancet Oncol (2013) 8.43

Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol (2007) 2.15

Progress against solid tumors in danger: the metastatic breast cancer example. J Clin Oncol (2012) 2.05

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol (2006) 1.60

Large vessel involvement in ANCA-associated vasculitides: report of a case and review of the literature. Clin Rheumatol (2004) 1.50

Metamizole use among Hispanics in Miami: report of a survey conducted in a primary care setting. South Med J (2006) 1.39

Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr Oncol Rep (2012) 1.17

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat (2010) 1.14

Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer. J Thorac Oncol (2014) 1.13

Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations. J Thorac Oncol (2014) 1.08

Primary ectopic breast cancer presenting as a vulvar mass. Clin Breast Cancer (2006) 1.01

Severe colitis associated with docetaxel use: A report of four cases. World J Gastrointest Oncol (2010) 1.01

Small-cell cancer of the breast: what is the optimal treatment? A report and review of outcomes. Clin Breast Cancer (2012) 0.93

A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer. Clin Breast Cancer (2008) 0.92

Impact of biomarkers on clinical trial risk in breast cancer. Breast Cancer Res Treat (2012) 0.90

Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer (2006) 0.90

A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res Treat (2011) 0.90

Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer. J Thorac Oncol (2010) 0.86

Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer. Clin Breast Cancer (2005) 0.86

A call for action to improve access to care and treatment for patients with rare diseases in the Asia-Pacific region. Orphanet J Rare Dis (2014) 0.86

Prevalence of hepatitis C infection in patients with non-Hodgkin's lymphoma in South Florida and review of the literature. Leuk Lymphoma (2004) 0.85

Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity. Head Neck (2006) 0.84

A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Cancer Chemother Pharmacol (2014) 0.82

Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group. Leuk Lymphoma (2006) 0.81

Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Am J Clin Oncol (2012) 0.81

Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat (2014) 0.81

Arsenic(V) removal with polymer inclusion membranes from sulfuric acid media using DBBP as carrier. Environ Sci Technol (2004) 0.79

Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab. J Clin Oncol (2007) 0.79

Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome. Am J Ther (2012) 0.79

Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study. Leuk Lymphoma (2002) 0.77

Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study. Clin Colorectal Cancer (2007) 0.77

A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer. Breast Cancer Res Treat (2013) 0.77

A myxoid chondrosarcoma associated with an anti-Hu-positive paraneoplastic encephalomyelitis. J Neurooncol (2010) 0.77

Successful use of biweekly gemcitabine plus nab-paclitaxel in two male patients with stage iv breast cancer: case reports and review of the literature. Am J Ther (2011) 0.76

Treatment of nasopharyngeal carcinoma in the modern era: analysis of outcomes and toxicity from a single center in a nonendemic area. Cancer J (2006) 0.76

Roles of cancer registries in enhancing oncology drug access in the Asia-Pacific region. Asian Pac J Cancer Prev (2013) 0.76

Dipyrone-induced granulocytopenia: a case for awareness. Pharmacotherapy (2006) 0.75

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma. Cancer (2002) 0.75

Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung cancer. J Clin Oncol (2005) 0.75

Rewarding innovation in drug discovery. Health Aff (Millwood) (2009) 0.75

Oncologic outcomes of neoadjuvant chemoradiation for locally advanced rectal cancer: a single-institution experience. Ann Acad Med Singapore (2014) 0.75

Surviving metastatic breast cancer for 18 years: a case report and review of the literature. Breast J (2011) 0.75